No profile data available.
Stoke Therapeutics, Inc. (STOK) is a healthcare company in the brain and nerve treatment drugs industry, based in Bedford, United States, with about 170 full-time employees.
It reported revenue of $184.42 million for fiscal year 2025, up 404.5% from fiscal year 2024, and net income of -$6.89 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $9.33 million, down 32.5% from a year before. Its market capitalization was $1.60 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
Stoke Therapeutics reported $184.42 million in revenue for fiscal year 2025, up 404.5% from $36.56 million in fiscal year 2024. In Q2 2026 revenue was $9.33 million.
$1.60 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Sarepta Therapeutics, Inc. (SRPT), Biohaven Ltd. (BHVN), Compass Pathways plc (CMPS), Rapport Therapeutics, Inc. (RAPP).